How have GBLX shares performed in 2023?

GB Sciences' stock was trading at $0.0176 at the start of the year. Since then, GBLX shares have decreased by 62.8% and is now trading at $0.0065. View the best growth stocks for 2023 here .

When is GB Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 1st 2024. View our GBLX earnings forecast .

How were GB Sciences' earnings last quarter?

GB Sciences, Inc. (OTCMKTS:GBLX) posted its quarterly earnings results on Monday, November, 14th. The company reported ($0.04) earnings per share (EPS) for the quarter.

What other stocks do shareholders of GB Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GB Sciences investors own include KushCo (KSHB) , Medical Marijuana (MJNA) , CNBX Pharmaceuticals (CNBX) , MassRoots (MSRT) , Surna (SRNA) , Gran Tierra Energy (GTE) , GreenGro Technologies (GRNH) , MariMed (MRMD) , Pennsylvania Real Estate Investment Trust (PEI) and Diamond Wellness (POTN) .

How do I buy shares of GB Sciences?

Shares of GBLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

GB Sciences Stock Price, News & Analysis (OTCMKTS:GBLX)

$0.0065

0.00 (0.00%)

(As of 11/29/2023 ET)

Compare

Today's Range: $0.0065
▼
$0.0069
50-Day Range: $0.0056
▼
$0.0118
52-Week Range: $0.01
▼
$0.03

Volume: 170,611 shs
Average Volume: 150,783 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Financials Headlines SEC Filings Short Interest

About GB Sciences Stock (OTCMKTS:GBLX)

GB Sciences, Inc., a phytomedical research and biopharmaceutical drug development company, engages in the research and development of plant-based medicines. The company offers cannabinoid-inspired medicines and complex therapeutic mixtures for the prescription drug market. Its intellectual property covers a range of medical conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.

GBLX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GBLX Stock News Headlines

November 26, 2023 | americanbankingnews.com

Contrasting GB Sciences (OTCMKTS:GBLX) and GlycoMimetics (NASDAQ:GLYC)

November 25, 2023 | americanbankingnews.com

Contrasting Oncolytics Biotech (NASDAQ:ONCY) & GB Sciences (OTCMKTS:GBLX)

November 30, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 2, 2023 | dailymail.co.uk

Team GB News: Medals and Schedule at Winter Olympics

October 8, 2023 | mirror.co.uk

Dan Wootton's replacement on GB News revealed as he's suspended over Laurence Fox rant

October 6, 2023 | mirror.co.uk

GB News boss explains why Dan Wootton is still on air amid allegations against presenter

October 3, 2023 | mirror.co.uk

GB News suspends third presenter for supporting Dan Wootton in Laurence Fox row

October 2, 2023 | dailymail.co.uk

GB News - Updates on the British television news channel

November 30, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

July 11, 2023 | finance.yahoo.com

Gb Sciences' First-in-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study at the University of Lethbridge

June 20, 2023 | reuters.com

INSIGHT-Lab crunch: British science has nowhere to go

May 27, 2023 | finance.yahoo.com

GBLX - GB Sciences, Inc.

March 20, 2023 | finance.yahoo.com

GB Sciences' First International Patent Protecting Its Proprietary Cannabinoid-Based Formulations for Parkinson's Disease Has Been Issued in China

March 7, 2023 | finance.yahoo.com

Successful 2022 Milestones Support Value of Gb Sciences' AI-Enabled Drug Discovery Platform

February 18, 2023 | benzinga.com

GB Sciences Stock (OTC:GBLX), Quotes and News Summary

December 26, 2022 | benzinga.com

Gb Sciences Identifies Novel Cannabis-Inspired Mixtures That Could Treat Viral Infections

December 12, 2022 | finance.yahoo.com

Gb Sciences Addresses Growing Need for Anxiety and Depression Medications With Non-Psychedelic, Kava-Based Formulations

November 1, 2022 | msn.com

Cannabis Terpenes Reduce Inflammation, Says Gb Sciences Study

November 1, 2022 | finance.yahoo.com

Gb Sciences Co-Publishes Study Demonstrating Anti-Inflammatory Properties of Cannabis Ingredients

October 27, 2022 | finance.yahoo.com

TODAY: Gb Sciences' President Demonstrates Benefits of AI-Enabled Drug Discovery Engine for Novel Plant-Inspired Pharmaceuticals at 10th Annual Drug Discovery Strategic Summit

October 24, 2022 | finance.yahoo.com

Gb Sciences' Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study

October 13, 2022 | finance.yahoo.com

TODAY: Gb Sciences' President Demonstrates Effectiveness of Simplified Therapeutic Mixtures Inspired by Cannabis Plant Extracts at Canna Pharma 2022 Conference

October 10, 2022 | msn.com

New Study Shows Promising Results In Treatment Of Parkinson's Disease With Cannabinoids

October 10, 2022 | finance.yahoo.com

Gb Sciences Co-Publishes Study Demonstrating Efficacy of Its Proprietary Cannabinoid Mixtures for the Treatment of Parkinson's Disease

September 6, 2022 | finance.yahoo.com

TODAY: Gb Sciences Describes Drug Development Progress in Pharma's Almanac Journal Article

August 9, 2022 | ca.finance.yahoo.com

GB Sciences, Inc. (GBLX)

July 20, 2022 | stockhouse.com

Gb Sciences Leads Digital Transformation in Biopharma Industry Through Its Novel AI-Accelerated Drug Discovery Platform-PhAROS(TM)

See More Headlines

Receive GBLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GB Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2016
Today: 11/30/2023
Next Earnings (Estimated): 2/01/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Biotechnology
Sub-Industry: Cannabis
Sector: Medical
Current Symbol: OTCMKTS:GBLX
CUSIP: N/A
CIK: 1165320
Web: gbsciences.com
Phone: (866) 721-0297
Fax: N/A
Employees: 3
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. John Claybron Poss (Age 75)
CEO, Interim CFO & Chairman
Comp: $60k
Dr. Andrea Small-Howard M.B.A. (Age 54)
MBA, Ph.D., Chairman of Scientific Advisory Board, Chief Science Officer, President & Director
Comp: $138k
Mr. Gary R. Henrie Esq. (Age 69)
Securities Counsel & Company Secretary

Key Competitors

View All Competitors

GBLX Stock Analysis - Frequently Asked Questions

How have GBLX shares performed in 2023?: GB Sciences' stock was trading at $0.0176 at the start of the year. Since then, GBLX shares have decreased by 62.8% and is now trading at $0.0065.
View the best growth stocks for 2023 here.
When is GB Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 1st 2024.
View our GBLX earnings forecast.
How were GB Sciences' earnings last quarter?: GB Sciences, Inc. (OTCMKTS:GBLX) posted its quarterly earnings results on Monday, November, 14th. The company reported ($0.04) earnings per share (EPS) for the quarter.

What other stocks do shareholders of GB Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other GB Sciences investors own include KushCo (KSHB), Medical Marijuana (MJNA), CNBX Pharmaceuticals (CNBX), MassRoots (MSRT), Surna (SRNA), Gran Tierra Energy (GTE), GreenGro Technologies (GRNH), MariMed (MRMD), Pennsylvania Real Estate Investment Trust (PEI) and Diamond Wellness (POTN).
How do I buy shares of GB Sciences?: Shares of GBLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:GBLX) was last updated on 11/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial